Knight Therapeutics | GUD - Interest Expense On Debt


Knight Therapeutics reported CAD3.92M in Interest Expense on Debt for its fiscal quarter ending in December of 2025.





Interest Expense On Debt Change Date
Akebia Therapeutics 362.52M 357.69M Mar/2026
Alaunos Therapeutics USD 1.07M 215K Jun/2023
Aurora Cannabis CAD 230K 1.88M Mar/2026
Avita Medical AUD 1.25M 100K Jun/2025
Canopy Growth CAD 12.31M 4.97M Mar/2026
Cronos Group USD 0 7K Sep/2024
Dianthus Therapeutics USD 4.44M 263K Sep/2024
Ionis Pharmaceuticals USD 17M 1000K Mar/2026
IQVIA Holdings USD 192M 1000K Mar/2026
Knight Therapeutics CAD 3.92M 1.56M Dec/2025
Moderna USD 11.49B 36B Mar/2026
Omeros USD 4.05M 5.16M Sep/2024
Organigram Holdings CAD 179K 127K Mar/2025
Organon & Co USD 111M 17M Mar/2026
Revvity USD 24.72M 1.2M Mar/2026
Tectonic Therapeutic USD 246.58M 246.56M Mar/2026
Tilray USD 6.7M 2.73M Jun/2025
Viatris USD 120.1M 500K Mar/2026
Xeris Pharmaceuticals USD 6.88M 269K Mar/2026